Impact of empiric antibiotic use on development of infections caused by extended-spectrum β-lactamase bacteria in a neonatal intensive care unit

Pediatric Infectious Disease Journal

Volumn 27, Issue 4, 2008, Pages 314-318

  Le, Jennifer ^a,b   Nguyen, Thuy ^b   Okamoto, Mark ^a   McKamy, Susan ^b   Lieberman, Jay M ^b,c  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b MILLER CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cefotaxime; Extended spectrum beta lactamase; Infants; Neonates; Tobramycin

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; BIRTH WEIGHT; CONFIDENCE INTERVAL; DEMOGRAPHY; FEMALE; GESTATIONAL AGE; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; NEWBORN INTENSIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 41649100549     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181606850     Document Type: Article

References (19)

1. National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470-485.
2. Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis. 2005;53:257-264.
3. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med. 2005;352:380-391.
4. Turner PJ. Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997-2003). Diagn Microbiol Infect Dis. 2004;50:291-293.
5. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med. 1993;119:353-358.
6. Pena C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1998;42:53-58.
7. Rice LB, Willey SH, Papanicolaou GA, et al. Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother. 1990;34:2193-2199.
8. Flidel-Rimon O, Friedman S, Gradstein S, Bardenstein R, Shinwell ES. Reduction in multiresistant nosocomial infections in neonates following substitution of ceftazidime with piperacillin/tazobactam in empiric antibiotic therapy. Acta Paediatr. 2003;92:1205-1207.
9. Jain A, Roy I, Gupta MK, Kumar M, Agarwal SK. Prevalence of extended-spectrum beta-lactamase-producing Gram-negative bacteria in septicaemic neonates in a tertiary care hospital. J Med Microbiol. 2003;52:421-425.
10. Kim YK, Pai H, Lee HJ, et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother. 2002;46:1481-1491.
11. Singh N, Patel KM, Leger MM, et al. Risk of resistant infections with Enterobacteriaceae in hospitalized neonates. Pediatr Infect Dis J. 2002;21:1029-1033.
12. Zaoutis TE, Goyal M, Chu JH, et al. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics. 2005;115:942-949.
13. de Man P, Verhoeven BA, Verbrugh HA, Vos MC, van den Anker JN. An antibiotic policy to prevent emergence of resistant bacilli. Lancet. 2000;355:973-978.
14. Datta N, Kontomichalou P. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature. 1965;208:239-241.
15. Stone PW, Gupta A, Loughrey M, et al. Attributable costs and length of stay of an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae outbreak in a neonatal intensive care unit. Infect Control Hosp Epidemiol. 2003;24:601-606.
16. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32:1162-1171.
17. Institute CaLS. Performance Standards for Antimicrobial Disk Susceptibility Tests. 2007. 17th Informational Supplement Document M100-S17.
18. Calil R, Marba ST, von Nowakonski A, Tresoldi AT. Reduction in colonization and nosocomial infection by multiresistant bacteria in a neonatal unit after institution of educational measures and restriction in the use of cephalosporins. Am J Infect Control. 2001;29:133-138.
19. Nijssen S, Bootsma M, Bonten M. Potential confounding in evaluating infection-control interventions in hospital settings: changing antibiotic prescription. Clin Infect Dis. 2006;43:616-623.